Orchard Therapeutics (NASDAQ:ORTX) and Polarityte (NASDAQ:PTE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, risk, institutional ownership and earnings.
Insider and Institutional Ownership
67.5% of Orchard Therapeutics shares are held by institutional investors. Comparatively, 32.6% of Polarityte shares are held by institutional investors. 8.4% of Polarityte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Orchard Therapeutics and Polarityte’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Orchard Therapeutics||$2.08 million||726.51||-$230.49 million||($10.22)||-1.54|
|Polarityte||$1.56 million||53.43||-$132.39 million||($4.86)||-0.63|
Polarityte has lower revenue, but higher earnings than Orchard Therapeutics. Orchard Therapeutics is trading at a lower price-to-earnings ratio than Polarityte, indicating that it is currently the more affordable of the two stocks.
This table compares Orchard Therapeutics and Polarityte’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
Orchard Therapeutics has a beta of -1.06, suggesting that its stock price is 206% less volatile than the S&P 500. Comparatively, Polarityte has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500.
This is a summary of recent recommendations and price targets for Orchard Therapeutics and Polarityte, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Orchard Therapeutics presently has a consensus price target of $26.20, indicating a potential upside of 66.77%. Polarityte has a consensus price target of $12.86, indicating a potential upside of 320.17%. Given Polarityte’s higher probable upside, analysts clearly believe Polarityte is more favorable than Orchard Therapeutics.
Polarityte beats Orchard Therapeutics on 7 of the 13 factors compared between the two stocks.
About Orchard Therapeutics
Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration. Its commercial stage products include Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-201 for mucopolysaccharidosis type IIIA and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Ltd. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
PolarityTE, Inc., a biotechnology and regenerative biomaterials company, focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services. It offers SkinTE, a tissue product for treatment of defects of the skin, as well as contract research services. The company also develops OsteoTE, an autologous homologous bone regeneration product; and CartTE, an autologous cartilage regeneration product. In addition, it develops AdipoTE to optimize the delivery of autologous fat; AngioTE for vascular regeneration; NeuralTE for peripheral nerve injuries of the extremities, as well as for patients with neuromas or chronic compression due to joint replacements, migraines, craniofacial injuries, carpal tunnel syndrome, and those who have undergone hernia or abdominal-based procedures; UroTE for the delivery of autologous urogenital epithelium and submucosa; LiverTE to address various causes of liver failure; and BowelTE to deliver an optimized autologous construct to aid in the regeneration of bowel tissue. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.
Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.